Smith & Nephew
About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Employees: 17,349
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
15% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 73
8% more capital invested
Capital invested by funds: $827M [Q4 2024] → $891M (+$63.4M) [Q1 2025]
4% more funds holding
Funds holding: 213 [Q4 2024] → 222 (+9) [Q1 2025]
0.26% less ownership
Funds ownership: 3.85% [Q4 2024] → 3.59% (-0.26%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
89% less call options, than puts
Call options by funds: $14K | Put options by funds: $133K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$28
5%
downside
Avg. target
$28
5%
downside
High target
$28
5%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Canaccord Genuity Caitlin Cronin | 5%downside $28 | Hold Maintained | 1 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1
Neutral
GlobeNewsWire
2 weeks ago
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA).
Neutral
GlobeNewsWire
1 month ago
Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week
Neutral
GlobeNewsWire
1 month ago
Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland
“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tour will commence in Berlin today and make dozens of stops at surgical facilities across Germany, Austria and Switzerland until returning to Berlin on 28 October for DKOU 2025 – the largest Orthopaedics congress in Europe.
Neutral
Seeking Alpha
1 month ago
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Julien Dormois - Jefferies Jack Reynolds-Clark - RBC Capital Markets Lisa Clive - Bernstein Hassan Al-Wakeel - Barclays Kane Slutzkin - Deutsche Bank David Adlington - JPMorgan Veronika Dubajova - Citi Dylan van Haaften - Stifel Robert Davies - Morgan Stanley Operator Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report. My name is Jenny, and I will be coordinating your call today.
Positive
Proactive Investors
1 month ago
Smith & Nephew shares jump 7% on better-than-expected quarterly growth
Smith & Nephew PLC (LSE:SN) rose as much as 7% in afternoon trading on Wednesday after the medical technology group reported stronger-than-expected revenue growth in the first quarter of 2025. The London-listed company posted underlying revenue growth of 3.1% in the three months to March, ahead market consensus of 1.9%.
Positive
Proactive Investors
1 month ago
Smith & Nephew jumps as hip and knee replacements in demand
Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year.
Positive
Zacks Investment Research
1 month ago
Is Smith & Nephew SNATS (SNN) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for April 29th
MATX, SNN, ALEX, PCB and LTH have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2025.
Positive
Seeking Alpha
1 month ago
Smith & Nephew: Underappreciated Recovery With Strategic Upside
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case suggests 50-60% upside with further margin gains.
Charts implemented using Lightweight Charts™